The potential role of somatostatin analogues in breast cancer treatment

Yale Journal of Biology and Medicine

Volumn 70, Issue 5-6, 1997, Pages 535-539

  Pollak, Michael ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

OCTREOTIDE; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; TAMOXIFEN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CLINICAL TRIAL; DRUG MECHANISM; HUMAN;

EID: 0031393588     PISSN: 00440086     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Schally, A.V. Oncological applications of somatostatin analogues. Cancer Res. 48: 6877-6885, 1988.
2. Weckbecker, G., Raulf, F., Stolz, B., and Bruns, C. Somatostatin analogs for diagnosis and treatment of cancer. Pharmacol. Then 60:245-264, 1993.
3. van Eijck, C.H., Krenning, E.P., Bootsma, A., Lindemans, J., Jeekel, J., Reubi, J.C., and Lamberts, S.W. Somatostatin-receptor scintigraphy in primary breast cancer. Lancet 343: 640-643, 1994.
4. Fekete, M., Wittliff, J.L., and Schally, A.V. Characteristics and distribution of receptors for [DTRP6]-luteinizing hormone-releasing hormone, somatostatin, epidermal growth factor, and sex steroids in 500 biopsy samples of human breast cancer. J. Clin. Lab. Anal. 3:137-147, 1989.
5. Grigorakis, S., Robertson, L., Watson, P., and Patel, Y.C. Expression of mRNA for five somatostatin receptor subtypes in human breast cancer. Proceedings of European Federation of Endoctrine Societies Somatostatin Analogue Congress, Sorento, Italy. 1995. (Abstract).
6. Setyono-Han, B., Henkelman, M.S., Foekens, J.A., and Klijn, G.M. Direct inhibitory effects of somatostatin (analogues) on the growth of human breast cancer cells. Cancer Res. 47:1566-1570, 1987.
7. Patel, Y.C. and Srikant, C.B. Subtype selectivity of peptide analogs for all five cloned human somatostatin receptors (hsstr 1-5). Endocrinology 135:2814-2817, 1994.
8. Lamberts, S.W., van der Lely, A., Deherder, W.W., and Hofland, L.J. Drug therapy: octreotide. N. Engl. J. Med. 334:246-254, 1996.
9. Patel, Y.C., Greenwood, M.T., Panetta, R., Demchyshyn, L., Niznik, H., and Srikant, C.B. The somatostatin receptor family. Life Sci. 57:1249-1265, 1995.
10. Buscail, L., Delesque, N., Esteve, J.P., Saint-Laurent, N., Prats, H., Clerc, P., Robberecht, P., Bell, G.I., Liebow, C., Schally, A.V., et al. Stimulation of tyrosine phosphatase and inhibition of cell proliferation by somatostatin analogues: mediation by human somatostatin receptor subtypes SSTRI and SSTR2. Proceedings of the National Academy of Sciences of the United States of America, 91:2315-2319, 1994.
11. Sharma, K., Patel, Y.C., and Srikant, C. Subtype specific induction of wild type p53 and apoptosis, but not cell cycle arrest, by human somatostatin receptor 3. Mol. Endocrinol. 10:1688-1696, 1996.
12. Cohick, W.S. and Clemmons, D.R. The insulin-like growth factors. Annu. Rev. Physiol. 55:131-153,1993.
13. Jones, J.I. and Clemmons, D.R. Insulin-like growth factors and their binding proteins: biological actions. Endocr. Rev. 16:3-34, 1995.
14. Resnicoff, M., Abraham, D., Yutanawiboonchai, W., Rotman, H.L., Kajstura, J., Rubin, R., Zoltick, P., and Baserga, R. The insulin-like growth factor I receptor protects tumor cells from apoptosis in vivo. Cancer Res. 55:2463-2469, 1995.
15. Macaulay, V.M. Insulin-like growth factors and cancer. Br. J. Cancer. 65 311-320, 1992.
16. Pollak, M., Polychronakos, C., Yousefi, S., and Richard, M. Characterization of insulin-like growth factor (IGF-I) receptors of human breast cancer cells. Biochem. Biophys. Res. Commun. 154:326-331, 1988.
17. Arteaga, C.L., Kitten, L.J., Coronado, E.B., Jacobs, S., Kull, F.C., Allred, D.C., and Osborne, C.K. Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice. J. Clin. Invest. 84:1418-1423, 1989.
18. Yang, X.F., Beamer, W., Huynh, H.T., and Pollak, M. Reduced growth of human breast cancer xenografts in hosts homozygous for the "lit"mutation. Cancer Res. 56:1509-1511, 1996.
19. Pollak, M., Polychronakos, C., and Guyda, H. Somatostatin analogue SMS 201-995 reduces serum IGF-I levels in patients with neoplasms potentially dependent on IGF-I. Anticancer Res. 9:889-892, 1989.
20. Tannenbaum, G.S., Gurd, W., Lapointe, M., and Pollak, M. Tamoxifen attenuates pulsatile growth hormone secretion: mediation in part by somatostatin. Endocrinology 130:3395-3401, 1992.
21. Malaab, S.A., Pollak, M., and Goodyer, C.G. Direct effects of tamoxifen on growth hormone secretion by pituitary cells in vitro. Eur. J. Cancer. 28A:788-793, 1992.
22. Pollak, M., Costantino, J., Polychronakos, C., Blauer, S., Guyda, H., Redmond, C., Fisher, B., and Margolese, R. Effect of tamoxifen on serum insulin-like growth factor I levels in stage I breast cancer patients. J. Natl. Cancer Inst. 82:1693-1697, 1990.
23. Huynh, H.T., Tetenes, E., Wallace, L., and Pollak, M. In vivo inhibition of insulin-like growth factor-I gene expression by tamoxifen. Cancer Res. 53:1727-1730, 1993.
24. Peyrat, J.P., Bonneterre, J., Beuscart, R., Djiane, J., and Demaille, A. Insulin-like growth factor I receptors in human breast cancer and their relation to estradiol and progesterone receptors. Cancer Res. 48:6429-6433, 1988.
25. Ezzat, S., Ren, S.G., Braunstein, G.D., and Melmed, S. Octreotide stimulates insulin-like growth factor-binding protein-1: a potential pituitary-independent mechanism for drug action. J. Clin. Endocrinol. Metab. 75:1459-1463, 1992.
26. Huynh, H.T., Yang, X.F., and Pollak, M. Estradiol and antiestrogens regulate a growth inhibitory insulin-like growth factor binding protein 3 autocrine loop in human breast cancer cells. J. Biol. Chem. 271:1016-1021, 1996.
27. Huynh, H.T., Yang, X.F., and Pollak, M. A role for insulin-like growth factor binding protein 5 in the antiproliferative action of the antiestrogen ICI 182780. Cell Growth and Differ. 7:1501-1506, 1996.
28. Stoll, B. Breast cancer risk in Japanese women with special reference to the growth hormoneinsulin-like growth factor axis. Jpn. J. Clin. Oncol. 22:1-5, 1992.
29. deWaard, F., Cornelis, J., Aoki, K., and Yoshida, M. Breast cancer incidence according to weight and height in two cities of the Netherlands and in Aichi prefecture, Japan. Cancer. 40:1269-1275, 1995.
30. Vatten, L., Kvikstad, A., and Nymoen, E. Incidence and mortality of breast cancer related to body height and living conditions during childhood and adolescence. Eur. J. Cancer. 28:128-13 1, 1992.
31. Murata, M., Kuno, K., and Sakamoto, G. Epidemiology of family predisposition for breast cancer in Japan. J. Natl. Cancer Inst. 69:1229-1234, 1982.
32. Tretli, S. Height and weight in relation to breast cancer morbidity and mortality: a prospective study of 570,000 women in Norway. Int. J. Cancer. 44:23-30, 1989.
33. Vatten, L.J. and Kvinnsland, S. Body height and risk of breast cancer: a prospective study of 23,831 Norwegian women. Br. J. Cancer, 61:881-885, 1990.
34. Hunter, D. and Willett, W. Diet, body size, and breast cancer. Epidemiol. Rev. 15:110-132, 1993.
35. Ziegler, R.G., Hoover, R.N., Nomura, A.M., West, D.W., Wu, A.H., Pike, M.C., Lake, A.J., Horn-ross, D.L., Kolonel, L.N., Siiteri, P.K., and Fraumeni, J.F. Relative weight, weight change, height, and breast cancer risk in Asian-American women. J. Natl. Cancer Inst. 88:650-660, 1996.
36. Juul, A., Bang, P., Hertel, N., Main, D., Dalgaard, P., Jorgensen, K., Muller, J., Hall, K., and Skakkeback, N.B. Serum insulin-like growth factor I in 1030 healthy children, adolescents, and adults: relation to age, sex, stage of puberty, testicular size, and body mass index. J. Clin. Endocrinol. Metab. 78:744-752, 1995.
37. Vennin, P., Peyrat, J.P., Bonneterre, J., Louchez, M.M., Harris, A.G., and Demaille, A. Effect of the long-acting somatostatin analogue SMS 201-995 (Sandostatin) in advanced breast cancer. Anticancer Res. 9:153-155, 1989.
38. Weckbecker, G., Tolcsvai, L., Stolz, B., Pollak, M., and Bruns, C. Somatostatin analogue octreotide enhances the antineoplastic effects of tamoxifen and ovariectomy on 7,12-dimethylbenz(a)anthracene-induced rat mammary carcinomas. Cancer Res. 54:6334-6337, 1994.
39. Huynh, H.T. and Pollak, M. Enhancement of tamoxifen-induced suppression of insulin-like growth factor I gene expression and serum level by a somatostatin analogue. Biochem. Biophys. Res. Comm. 203:253-259, 1994.
40. Pollak, M., Ingle, J.N., Suman, V.J., Kugler, J.W., Nickerson, T., and Deroo, B. Enhancement of tamoxifen-induced suppression of serum IGF-I levels in metastatic breast cancer patients by coadministration of the somatostatin analogue octreotide. American Association for Cancer Research Annual Meeting, Washington D.C. 1996.